Roche: FDA approves new targeted breast cancer drug
(CercleFinance.com) - US regulators have approved a new subcutaneous drug for the treatment of breast cancer for Roche, giving patients a new treatment based on their individual needs and preferences.
The US Food and Drug Administration (FDA) has approved Herceptin Hylecta for injection for the treatment of certain people with HER2-positive early breast cancer in combination with chemotherapy.
The FDA's decision also concerns HER2-positive metastatic breast cancer in combination with paclitaxel or alone in people who have one or more chemotherapy.
Herceptin Hylecta is a ready-to-use formulation that can be administered in two to five minutes, compared to 30 to 90 minutes for the intravenous cancer drug Herceptin.
Copyright (c) 2019 CercleFinance.com. All rights reserved.
The US Food and Drug Administration (FDA) has approved Herceptin Hylecta for injection for the treatment of certain people with HER2-positive early breast cancer in combination with chemotherapy.
The FDA's decision also concerns HER2-positive metastatic breast cancer in combination with paclitaxel or alone in people who have one or more chemotherapy.
Herceptin Hylecta is a ready-to-use formulation that can be administered in two to five minutes, compared to 30 to 90 minutes for the intravenous cancer drug Herceptin.
Copyright (c) 2019 CercleFinance.com. All rights reserved.